CTP-543

Concert to seek approval for hair loss drug after second study success
BioPharma Dive
Mon, 08/1/22 - 10:49 am
Concert Pharmaceuticals
FDA
hair loss
clinical trials
CTP-543
Chasing Lilly and Pfizer, Concert's JAK inhibitor hits high notes in phase 3 alopecia trial
Fierce Biotech
Mon, 05/23/22 - 10:36 am
Concert Pharmaceuticals
clinical trials
alopecia areata
Eli Lilly
Pfizer
CTP-543
Chasing Lilly, Concert eyes 2023 filing for its JAK drug for alopecia
Pharmaforum
Fri, 05/28/21 - 11:10 am
Concert Pharmaceuticals
alopecia
clinical trials
CTP-543
Concert gets BTD for alopecia drug, setting up a late-stage showdown with giant rival Pfizer
Endpoints
Wed, 07/8/20 - 10:45 am
Concert Pharmaceuticals
alopecia areata
FDA
CTP-543
breakthrough therapies
Concert Pharmaceuticals completes enrollment in second open label trial of CTP-543 in alopecia areata
Pharmaceutical Business Review
Wed, 09/18/19 - 10:05 am
Concert Pharmacueticals
clinical trials
CTP-543
alopecia areata
With FDA’s Eye on JAK Drugs, Concert Moves One Ahead For Hair Loss
Xconomy
Tue, 09/3/19 - 10:28 am
Concert Pharmaceuticals
Pfizer
JAK inhibitors
CTP-543
alopecia areata
Concert’s initial alopecia data fall short against Pfizer, prompting investor blow back
Endpoints
Tue, 11/13/18 - 09:50 am
Concert Pharmaceuticals
alopecia
JAK inhibitors
Pfizer
CTP-543
Concert rethinks R&D plans after loss in Incyte patent case
Fierce Biotech
Fri, 01/12/18 - 06:40 pm
Concert Pharmaceuticals
Incyte
patents
R&D
CTP-543
After a quick trial revamp, FDA lifts its clinical hold on Concert’s hair-loss drug
Endpoints
Mon, 07/10/17 - 09:24 am
FDA
clinical trials
Concert Pharmaceuticals
CTP-543
alopecia areata
hair loss
FDA forces Concert Pharma to hit the brakes on a mid-stage study so it can review tox studies
Endpoints
Wed, 05/17/17 - 09:34 am
FDA
Concert Pharmaceuticals
clinical trials
CTP-543
alopecia areata